UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in ...
News Medical on MSN
Scientists identify ANKIB1 as key regulator of innate immune signaling
Innate immune sensors – known as pattern recognition receptors (PRRs) – detect specific molecular components of bacterial or viral intruders. The PRRs forward the signals which results in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results